CONDENSED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Revenue:
License revenue	$ 0	$ 0	$ 150,000	$ 0
Expenses:
Research and development	3,220,098	2,845,181	9,927,458	7,964,049
General and administrative	1,739,148	1,848,028	5,913,209	6,553,404
Total Expenses	4,959,246	4,693,209	15,840,667	14,517,453
Loss before other income	(4,959,246)	(4,693,209)	(15,690,667)	(14,517,453)
Other income:
Interest income	56,452	71,947	162,151	244,668
Other income, net	28,468	25,697	81,118	61,394
Gain on warrant derivative liability	4,316,560	181,499	5,494,322	1,593,076
Gain on sale of affiliate's shares - RXi Pharmaceutical	0	0	0	8,887,614
Loss before provision for income taxes	(557,766)	(4,414,066)	(9,953,076)	(3,730,701)
Provision for income taxes	0	0	0	0
Net loss	(557,766)	(4,414,066)	(9,953,076)	(3,730,701)
Other comprehensive income (loss) (net of tax)
Unrealized gain (loss) on available-for-sale securities	(263,340)	773,470	115,920	8,817,561
Comprehensive income (loss)	$ (821,106)	$ (3,640,596)	$ (9,837,156)	$ 5,086,860
Basic and diluted net loss per share (in dollars per share)	$ 0.00	$ (0.04)	$ (0.08)	$ (0.03)
Basic and diluted weighted-average shares outstanding (in shares)	134,792,286	109,131,738	117,842,198	109,055,634